Innoviva, Inc. (INVA)

Market Cap	1.72B +59.3%
Revenue (ttm)	411.33M +14.7%
Net Income	271.17M +1,059.2%
EPS	3.30 +811.8%
Shares Out	74.05M
PE Ratio	7.05
Forward PE	11.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	531,622
Open	22.95
Previous Close	23.02
Day's Range	22.75 - 23.39
52-Week Range	16.52 - 25.15
Beta	0.40
Analysts	Buy
Price Target	32.80 (+40.89%)
Earnings Date	May 6, 2026

About INVA

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2004
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: INVA
• Website: https://www.inva.com

Financial Performance

In 2025, Innoviva's revenue was $411.33 million, an increase of 14.67% compared to the previous year's $358.71 million. Earnings were $271.17 million, an increase of 1059.22%.

Analyst Summary

According to 5 analysts, the average rating for INVA stock is "Buy." The 12-month stock price target is $32.8, which is an increase of 40.89% from the latest price.

Price Target

$32.8

(40.89% upside)

Analyst Consensus: Buy